Who are Chemotherapy+Pembrolizumab.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SOX plus PD-1 inhibitor, TPC combined with Tislelizumab, Standard dose: standard XELOX + sintilimab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chemotherapy-pembrolizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Chemotherapy+Pembrolizumab. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy+Pembrolizumab. (Chemotherapy+Pembrolizumab.) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy + PD-1 inhibitor combination. Area: Oncology.

marketed Chemotherapy + PD-1 inhibitor combination PD-1 (programmed death receptor 1); chemotherapy targets DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Chemotherapy+Pembrolizumab. (Chemotherapy+Pembrolizumab.) — Tang-Du Hospital. Chemotherapy kills rapidly dividing cancer cells while pembrolizumab blocks PD-1 to enhance immune recognition and destruction of remaining tumor cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Chemotherapy+Pembrolizumab. TARGET	Chemotherapy+Pembrolizumab.	Tang-Du Hospital	marketed	Chemotherapy + PD-1 inhibitor combination	PD-1 (programmed death receptor 1); chemotherapy targets DNA
SOX plus PD-1 inhibitor	SOX plus PD-1 inhibitor	Liaoning Cancer Hospital & Institute	marketed	Chemotherapy + PD-1 inhibitor combination	PD-1 (programmed death receptor 1); S-1 (thymidylate synthase/5-FU metabolism); oxaliplatin (DNA cross-linking)
TPC combined with Tislelizumab	TPC combined with Tislelizumab	XIANG YANQUN	phase 3	Chemotherapy + PD-1 inhibitor combination	PD-1 (Tislelizumab component); TPC targets DNA/cell cycle
Standard dose: standard XELOX + sintilimab	Standard dose: standard XELOX + sintilimab	Sun Yat-sen University	phase 3	Chemotherapy + PD-1 inhibitor combination	PD-1 (sintilimab component); DNA/thymidylate synthase (XELOX component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy + PD-1 inhibitor combination class)

Liaoning Cancer Hospital & Institute · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Tang-Du Hospital · 1 drug in this class
XIANG YANQUN · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chemotherapy+Pembrolizumab. — Competitive Intelligence Brief. https://druglandscape.com/ci/chemotherapy-pembrolizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab